Introduction: Computer-aided diagnosis (CAD) powered by artificial intelligence is attracting increased attention as an option to improve the performance of optical biopsy for evaluating colorectal polyps [1] . Although positive preliminary data have been shown for applying CAD to endocytoscopy (EC) (500-fold ultramagnifying endoscopy; Olympus Corp., Tokyo, Japan) [2, 3] , no prospective studies have been reported.
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Aims & Methods:
The present study is an initial prospective trial to validate the feasibility of applying CAD to endocytoscopy in a routine colonoscopy practice. A total of 88 patients (38 women, 50 men; mean age 64 years) in whom colorectal polyps had been detected using EC for colonoscopy were prospectively enrolled in the study between January and March 2017. When a polyp was detected, an on-site endoscopist predicted the polyp pathology using the CAD system [2] , which was designed to output the predicted pathology of the target lesionwhether neoplastic or non-neoplastic-together with the probability of the diagnosis (0-100%) immediately after obtaining a methylene blue-stained EC image. The endoscopists obtained as many images as they thought were needed, each of which was evaluated using image-based analysis. The diagnostic ability of the CAD for each image was assessed with reference to the final pathology of the resected specimen. The main outcome measures were diagnostic sensitivity specificity, accuracy, positive predictive value, and negative predictive value of the CAD system for identifying neoplastic change with high confidence (probability !90%). Prior to initiating the trial, 13,861 EC images were used for machinelearning the CAD model. Results: Overall, 126 lesions (62 neoplastic lesions, 64 non-neoplastic lesions; mean size 6 mm) were detected, all of which were successfully analyzed using the CAD system. A total of 1014 EC images of neoplastic lesions and 1480 EC images of non-neoplastic lesions were obtained during the colonoscopies of these patients. Among them, 55% (1378/2494) were diagnosed with high confidence (CAD probability was !90%). The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of the CAD system in identifying neoplastic change with high confidence were 97%, 67%, 83%, 78%, and 95%, respectively ( ). We found that a 16.6 kb inversion in the CTRB1-CTRB2 locus was in linkage disequilibrium with the CPassociated SNPs and best tagged by rs8048956. The association was also successfully replicated in three independent European non-alcoholic CP cohorts of 1, 650 patients and 6695 controls (odds ratio, 1.62 [95% CI 1.42 to 1.86]; P ¼ 1.64 Â 10 À12 ). The inversion changes the expression ratio of CTRB1 and CTRB2 isoforms and thereby affects protective trypsinogen degradation and ultimately pancreatitis risk. Conclusion: Our GWAS identified CTRB1-CTRB2 as a new risk locus for ACP and NACP. The association within the CTRB1-CTRB2 locus was linked to a 16.6 kb inversion that altered CTRB1/CTRB2 expression thereby affecting protective trypsinogen degradation. Furthermore, we confirmed association of ACP with the PRSS1-PRSS2, CLDN2-MORC4, CTRC and SPINK1 loci. Taken together, the identified risk variants explained about 18% of the variance in ACP. Our discovery provides strong evidence for common pathogenic mechanisms underlying the complex etiology of ACP and NACP. Disclosure of Interest: All authors have declared no conflicts of interest.
